

Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy

David M. Francis, Susan N. Thomas

PII: S0169-409X(17)30046-7
DOI: doi:10.1016/j.addr.2017.04.011
Reference: ADR 13106

To appear in: *Advanced Drug Delivery Reviews*

Received date: 16 February 2017
Revised date: 12 April 2017
Accepted date: 14 April 2017

Please cite this article as: David M. Francis, Susan N. Thomas, Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy, *Advanced Drug Delivery Reviews* (2017), doi:10.1016/j.addr.2017.04.011

Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy

David M. Francis[1,2] and Susan N. Thomas[2,3,4,5]*

[1]School of Chemical and Biomolecular Engineering, [2]Parker H. Petit Institute for Bioengineering and Bioscience, [3]George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, Georgia; [4]Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia; [5]Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia

Running Title: Enhancing Delivery of Checkpoint Inhibitor mAb

Keywords: cytotoxic T lymphocyte antigen-4, programmed cell death-1, cancer immunotherapy, tumor immunology, lymph node, drug delivery systems, controlled release, therapeutic antibody, immune-related associated toxicity

Financial Support: This work was supported by National Institutes of Health (NIH) Grant R01CA207619, CCR15330478 grant from Susan G. Komen®, and Department of Defense Grant CA150523.

To whom correspondence should be addressed:

Susan N. Thomas, Ph.D.
George W. Woodruff School of Mechanical Engineering
Georgia Institute of Technology
315 Ferst Drive NW
Atlanta, GA 30332
Tel: +1 (404) 385-1126
Fax: +1 (404) 385-1397
E-mail: susan.thomas@gatech.edu